Sympathetic denervation in patients with ischemic cardiomyopathy and risk on ventricular tachy-arrhythmias. A pilot

Walter Noordzij1, Arif Elvan2, Fatma Demirel2

  • 1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands - w.noordzij@umcg.nl.

Insights

Cardiac sympathetic denervation is impaired in ischemic cardiomyopathy patients. Large denervated areas detected by [11C]-mHED imaging predict all-cause mortality, suggesting a role beyond LVEF for risk stratification.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Ischemic cardiomyopathy (ICM) patients face ventricular arrhythmia risks, often managed with implantable cardioverter defibrillators (ICDs).
  • Left ventricular ejection fraction (LVEF) is a key metric, but cardiac sympathetic innervation visualization may offer additional prognostic value.
  • This study investigated the role of sympathetic denervation in ventricular arrhythmia development in ICM patients.

Purpose of the Study:

  • To assess the role of sympathetic denervation in the genesis of ventricular arrhythmias in patients with ischemic cardiomyopathy.
  • To explore if cardiac sympathetic innervation imaging can enhance risk stratification for ICD therapy.

Main Methods:

  • Twenty ICM patients with LVEF <30% were enrolled and stratified by arrhythmia history.
  • Cardiac sympathetic denervation was assessed using carbon-11 labelled meta-hydroxy-ephedrine ([11C]-mHED) imaging.
  • Myocardial ischemia, viability, and [11C]-mHED retention were evaluated, with follow-up for one year.

Main Results:

  • No significant difference in global [11C]-mHED retention was observed between patients with and without a history of arrhythmias.
  • Seven patients developed ventricular arrhythmias, and four died during the follow-up period.
  • A larger size of the denervated area, identified by [11C]-mHED defects, was significantly associated with all-cause mortality (P=0.002).

Conclusions:

  • Cardiac sympathetic innervation is demonstrably impaired in patients with ischemic cardiomyopathy.
  • Extensive sympathetic denervation, visualized via [11C]-mHED imaging, is linked to increased all-cause mortality in ICM.
  • These findings suggest sympathetic denervation imaging may improve risk stratification for ICM patients.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
738
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
652
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K